cryptos 2022 Block

I announced the independence of Neo series, and the price of Neo7 started from 2099 yuan. On the evening of December 12, I recently held a new product launch conference, announcing the official independence of Neo series, positioning the flagship of e-sports for young people who know better, and releasing the first new product in the series-Neo7 for me, starting from 2099 yuan in a limited time. (Sina Technology)Wanchen Group: It is planned to purchase 16 "New Zero Help" software systems of Nanjing Zhongcheng for 27.7031 million yuan. Wanchen Group announced that in order to meet the needs of the company and its holding subsidiaries to carry out daily business activities, the company plans to purchase 16 "New Zero Help" software systems held by Nanjing Zhongcheng at a transaction price of 27.7031 million yuan (including tax). Nanjing Zhongcheng is a related party of the company, and this transaction constitutes a related party transaction. According to the announcement, the software system is specially designed for retail and wholesale enterprises, mainly for medium and large retail enterprises.CITIC Securities: The resonance between supply and demand of medical beauty accelerates the space expansion, and the difference in operating ability promotes the evolution of the industry structure. CITIC Securities Research Report stated that the medical beauty industry has both medical and consumption attributes, and the medical attribute has strong product-driven characteristics, while the consumption attribute has high operating ability requirements. The medical beauty botulinum toxin track is also affected by the dual attributes of medicine and consumption: 1) The increase in penetration rate, the acceleration of compliance substitution and the extension of indications have brought about high demand for medical beauty botulinum toxin, and with the recent supply expansion, the industry scale has experienced high growth; 2) The iteration of product innovation is slow, brand barriers are created through marketing, doctors are empowered through direct sales, and control is strengthened to enhance product competitiveness. Recently, a variety of medical botulinum toxins in China have been approved, and the promotion of low-priced products is expected to push up the penetration rate, and enterprises with strong operational capabilities will enter the market or promote the evolution of the pattern.

Shan Ying International: It is proposed to raise the share repurchase price ceiling to 3 yuan/share. Shan Ying International (600567) announced on the evening of December 12 that it intends to adjust the share repurchase price ceiling from 2.34 yuan/share to 3 yuan/share.Laimei Pharmaceutical Co., Ltd.: The controlling shareholder intends to transfer 23.43% of the shares by agreement. Laimei Pharmaceutical announced that Zhongheng Group, the controlling shareholder, intends to transfer 247 million shares of the company's unrestricted tradable A shares by public solicitation of the transferee, accounting for 23.43% of the company's total share capital, and the transfer price is not less than 4.42 yuan/share. If the share transfer is completed, the controlling shareholder and actual controller of the company may change.Market News: A fire broke out at Kaliningrad Shipyard in Russia.

Polish Prime Minister Tusk told French President Macron that even if Russia and Ukraine cease fire, Polish troops will not enter Ukraine. The tenth batch of national procurement officially opened, and the number of enterprises and varieties involved reached a record high. The tenth batch of centralized drug procurement organized by the state officially accepted the application materials of enterprises at 8: 00 this morning at No.398 Zhanyuan Road, Nanqiao New Town, Fengxian District, Shanghai. This centralized procurement involved 62 varieties and 263 product specifications, and the number of enterprises and varieties involved reached a record high. Among them, 33 enterprises competed for nine short-listed oral sustained-release formulations of sitagliptin. There are also a number of varieties that are billions in the market of public hospitals, such as doxorubicin hydrochloride liposome injection, cefoperazone injection, piperacillin injection, compound α -ketoacid oral sustained-release dosage form, norepinephrine injection and aspirin oral sustained-release dosage form. The sales scale in sample hospitals last year all exceeded 2 billion yuan. Hengrui Pharma, Kelun Pharmaceutical, Unacon and Zhengda Tianqing participated with many varieties. Note: According to the tenth batch of national adoption documents released before, the tenth batch of national adoption rules have changed a lot, such as canceling the protection mechanism of 50% price reduction and increasing the fuse recovery mechanism by 1.8 times, and the number of B-certified enterprises affects the number of final finalists.